Xenon Pharmaceuticals Inc.

By person

23 insiders · 217 transactions

2.6×

Ian Mortimer holds only 2.6 times base salary in stock. $2.09M of shares against $786.00K in salary for 2025.

Salary from the company's own proxy. The shares are what Ian Mortimer last reported holding, valued at $60.98, the price Common Shares was last bought or sold at on the open market here, on 28 Aug 2026.

Insider

Role

Bought

Sold

Net

Holding

Of company

Worth

Change

MORTIMER IAN

PRESIDENT & CEO

$43.23K (2)

$24.82M (25) scheduled

−$24.78M

34,223

0.0353%

$2.09M

+545.7%

PIMSTONE SIMON N.

Director

$17.40K (1)

$14.96M (34)

−$14.95M

6,000

0.0062%

$365.86K

−97.2%

EMPFIELD JAMES R.

EVP, Drug Discovery

$24.82K (1)

$3.78M (5) scheduled

−$3.75M

10,000

0.0103%

$609.77K

—

ROBIN SHERRINGTON

EVP, Strategy & Innovation

—

$3.61M (11) scheduled

−$3.61M

8,398

0.0087%

$512.08K

+108.8%

BVF PARTNERS L P/IL entity

10% owner

$2.05M (28)

—

+$2.05M

59,464

0.0614%

$3.63M

−96.9%

AULIN SHERRY

Chief Financial Officer

—

$1.38M (3) scheduled

−$1.38M

0.0000%

$0.00

—

GANNON STEVEN

Director

$42.27K (1)

$1.24M (6)

−$1.20M

1,870

0.0019%

$114.03K

—

PATOU GARY

Director

$35.84K (2)

$1.17M (9) scheduled

−$1.13M

29,798

0.0308%

$1.82M

+647.6%

Svoronos Dawn

Director

$140.77K (1)

$967.50K (1)

−$826.73K

31,373

0.0324%

$1.91M

—

KENNEY CHRISTOPHER JOHN

Chief Medical Officer

$20.17K (1)

$694.76K (5) scheduled

−$674.60K

<0.0001%

$121.95

+100.0%

HOLLER FRANK A

Director

—

$649.32K (7)

−$649.32K

143,653

0.1483%

$8.76M

−1.5%

DiFabio Andrea

Chief Legal Officer

—

$230.81K (2) scheduled

−$230.81K

7,301

0.0075%

$445.19K

—

Von Seggern Christopher

Chief Commercial Officer

$97.60K (1)

—

+$97.60K

4,000

0.0041%

$243.91K

—

GAROFALO ELIZABETH A.

Director

—

$95.58K (1) scheduled

−$95.58K

2,645

0.0027%

$161.28K

—

AZAB MOHAMMAD

Director

$81.14K (5)

$214.18 (1)

+$80.93K

74,225

0.0766%

$4.53M

+1,403%

Cannon Gillian

Director

—

$63.24K (1) scheduled

−$63.24K

1,455

0.0015%

$88.72K

—

Hayden Michael R

Director

$41.25K (1)

—

+$41.25K

208,282

0.2151%

$12.70M

+169.4%

SCHELLER RICHARD H

Director

$19.95K (1)

—

+$19.95K

7,000

0.0072%

$426.84K

—

WINQUIST RAYMOND

Head, Translational Research

$3.00K (1)

—

+$3.00K

1,000

0.0010%

$60.98K

—

TARNOW MICHAEL M

Director

—

77,942

0.0805%

$4.75M

+41.3%

COHEN CHARLES J.

VP, Biology

—

6,550

0.0068%

$399.40K

—

Machado Patrick

Director

—

2,645

0.0027%

$161.28K

—

Gover Justin D.

Director

—

2,645

0.0027%

$161.28K

—

Individual transactions

Insider

Date

Role

Action

Price

Amount

KENNEY CHRISTOPHER JOHN

21 Jan 2022

Chief Medical Officer

Buy

700

$28.81

$20.17K

Von Seggern Christopher

6 Dec 2021

Chief Commercial Officer

Buy

4,000

$24.40

$97.60K

AZAB MOHAMMAD

15 Nov 2017

Director

Buy

15,000

$2.22

$33.28K

AZAB MOHAMMAD

22 Sep 2017

Director

Buy

8,000

$2.95

$23.60K

AZAB MOHAMMAD

21 Sep 2017

Director

Buy

2,000

$2.95

$5.90K

WINQUIST RAYMOND

18 Aug 2017

Head, Translational Research

Buy

1,000

$3.00

$3.00K

AZAB MOHAMMAD

18 Aug 2017

Director

Buy

6,312

$2.90

$18.30K

AZAB MOHAMMAD

17 Aug 2017

Director

Buy

$2.65

$60.95

BVF PARTNERS L P/IL

15 Aug 2017

10% owner

Buy

7,429

$2.41

$17.92K

BVF PARTNERS L P/IL

15 Aug 2017

10% owner

Buy

11,429

$2.41

$27.57K

EMPFIELD JAMES R.

15 Aug 2017

SVP, Drug Discovery

Buy

10,000

$2.48

$24.82K

Hayden Michael R

14 Aug 2017

Director

Buy

15,000

$2.75

$41.25K

Svoronos Dawn

14 Aug 2017

Director

Buy

50,000

$2.82

$140.77K

BVF PARTNERS L P/IL

14 Aug 2017

10% owner

Buy

13,337

$2.70

$36.06K

BVF PARTNERS L P/IL

14 Aug 2017

10% owner

Buy

28,007

$2.70

$75.72K

GANNON STEVEN

11 Aug 2017

Director

Buy

15,000

$2.82

$42.27K

PIMSTONE SIMON N.

10 Aug 2017

President & CEO

Buy

6,000

$2.90

$17.40K

SCHELLER RICHARD H

10 Aug 2017

Director

Buy

7,000

$2.85

$19.95K

MORTIMER IAN

10 Aug 2017

CFO & COO

Buy indirect

10,000

$2.90

$29.00K

MORTIMER IAN

10 Aug 2017

CFO & COO

Buy

5,000

$2.85

$14.23K

PATOU GARY

10 Aug 2017

Director

Buy indirect

7,500

$2.78

$20.84K

PATOU GARY

8 Aug 2017

Director

Buy indirect

5,000

$3.00

$15.00K

BVF PARTNERS L P/IL

27 Jun 2017

10% owner

Buy

8,496

$4.00

$33.98K

BVF PARTNERS L P/IL

27 Jun 2017

10% owner

Buy

30,170

$4.00

$120.68K

BVF PARTNERS L P/IL

27 Jun 2017

10% owner

Buy

46,795

$4.00

$187.18K

BVF PARTNERS L P/IL

22 Jun 2017

10% owner

Buy

854

$4.00

$3.42K

BVF PARTNERS L P/IL

22 Jun 2017

10% owner

Buy

2,884

$4.00

$11.54K

BVF PARTNERS L P/IL

22 Jun 2017

10% owner

Buy

4,525

$4.00

$18.10K

BVF PARTNERS L P/IL

21 Jun 2017

10% owner

Buy

1,362

$4.00

$5.45K

BVF PARTNERS L P/IL

21 Jun 2017

10% owner

Buy

4,406

$4.00

$17.62K

BVF PARTNERS L P/IL

21 Jun 2017

10% owner

Buy

6,380

$4.00

$25.52K

BVF PARTNERS L P/IL

19 Jun 2017

10% owner

Buy

357

$3.85

$1.37K

BVF PARTNERS L P/IL

19 Jun 2017

10% owner

Buy

1,271

$3.85

$4.89K

BVF PARTNERS L P/IL

19 Jun 2017

10% owner

Buy

1,967

$3.85

$7.57K

BVF PARTNERS L P/IL

16 Jun 2017

10% owner

Buy

1,064

$3.85

$4.10K

BVF PARTNERS L P/IL

16 Jun 2017

10% owner

Buy

3,873

$3.85

$14.91K

BVF PARTNERS L P/IL

16 Jun 2017

10% owner

Buy

6,097

$3.85

$23.47K

BVF PARTNERS L P/IL

15 Jun 2017

10% owner

Buy

1,160

$3.84

$4.45K

BVF PARTNERS L P/IL

15 Jun 2017

10% owner

Buy

3,845

$3.84

$14.75K

BVF PARTNERS L P/IL

15 Jun 2017

10% owner

Buy

6,774

$3.84

$25.99K

BVF PARTNERS L P/IL

7 Jun 2017

10% owner

Buy

20,594

$3.85

$79.31K

BVF PARTNERS L P/IL

7 Jun 2017

10% owner

Buy

73,749

$3.85

$284.02K

BVF PARTNERS L P/IL

7 Jun 2017

10% owner

Buy

113,446

$3.85

$436.90K

BVF PARTNERS L P/IL

6 Jun 2017

10% owner

Buy

913

$3.75

$3.42K

BVF PARTNERS L P/IL

6 Jun 2017

10% owner

Buy

53,260

$3.75

$199.73K

BVF PARTNERS L P/IL

6 Jun 2017

10% owner

Buy

96,736

$3.75

$362.76K

Show all 217 transactions →

Xenon Pharmaceuticals Inc.

By person

Individual transactions

What was left out